Regeneration Technologies' bone fillers:
This article was originally published in Clinica
Regeneration Technologies has received US FDA 510(k) clearance to market its Sterling line of xenograft chips and cubes for filling in bony voids or gaps in the skeletal system, which can arise following surgery or traumatic injury. The products provide a scaffold for bone healing and become incorporated into the patient's own bone. They are rendered biocompatible and sterile using the company's patented BioCleanse tissue sterilisation process. The fillers should be available for distribution in late 2005, said the Alachua, Florida firm, which also makes implants for use in cardiovascular and other surgeries.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.